PHILADELPHIA, July 22, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics,?a clinical-stage cell therapy company, announces a recent publication by investigators at the University of Pennsylvania in the peer-reviewed journal, Science Immunology. The publication details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the company’s proprietary Senza5TM platform. This technology, developed by the University of Pennsylvania and exclusively licensed to Vittoria, leverages the therapeutic potential of CD5 modulation to enhance the efficacy of CAR T-cell therapies and underscores its utility across multiple hematological and solid tumor animal models.

See more here:
Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology